Lanreotide (Somatuline)

1. Overview

Lanreotide is a synthetic cyclic octapeptide analog of native somatostatin-14, developed by the French pharmaceutical company Beaufour-Ipsen (now Ipsen) as the second clinically available somatostatin analog after octreotide [5][12]. First marketed in Europe in the early 1990s as a conventional immediate-release formulation, lanreotide achieved its current clinical prominence with the development of the Autogel (marketed as Somatuline Depot in the United States), a revolutionary supersaturated aqueous gel formulation that enables deep subcutaneous self-injection every 28 days without the need for reconstitution or intramuscular administration [5][16][18].

The amino acid sequence of lanreotide is D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, cyclized by a disulfide bridge between the two cysteine residues. Its molecular formula is C54H69N11O10S2 with a molecular weight of 1096.34 Da [18]. Lanreotide shares the essential Tyr-D-Trp-Lys pharmacophore found in all clinically active somatostatin analogs but differs from octreotide in its N-terminal residue (D-2-naphthylalanine vs D-phenylalanine), position 6 (valine vs threonine), and C-terminal modification (threonine-amide vs threoninol) [7][12]. Despite these structural differences, lanreotide exhibits a nearly identical somatostatin receptor binding profile to octreotide, with high affinity for SSTR2 (Ki ~0.5-1.8 nM) and moderate affinity for SSTR5 (Ki ~5.2 nM), and minimal binding to SSTR1, SSTR3, and SSTR4 [7][8].

Lanreotide received FDA approval in 2007 for long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy, and in 2014 for the treatment of unresectable, well-differentiated or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, based on the landmark CLARINET trial [1][18]. It is also approved in Europe for carcinoid syndrome and thyroid-stimulating hormone-secreting pituitary adenomas.

Type

Somatostatin analog (cyclic octapeptide)

Molecular Weight

1096.34 Da (free base)

Molecular Formula

C₅₄H₆₉N₁₁O₁₀S₂

Sequence

D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (cyclic disulfide)

Half-life

23-30 days (Autogel deep SC); ~2 hours (IV)

Bioavailability

73-85% (deep subcutaneous, Autogel)

Routes

Deep subcutaneous (Autogel/Depot)

FDA Status

Approved (Somatuline Depot, 2007 for acromegaly; 2014 for GEP-NETs)

Approved Indications

Acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), carcinoid syndrome

2. Mechanism of Action

2.1 Somatostatin Receptor Agonism

Lanreotide functions as a high-affinity agonist at somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), two of the five G protein-coupled somatostatin receptors expressed throughout the endocrine, neuroendocrine, and gastrointestinal systems [7][8]. SSTR2 is the predominant receptor subtype on somatotroph adenomas, neuroendocrine tumor cells, and enteroendocrine cells, while SSTR5 is co-expressed in many of these tissues and contributes to hormonal and growth-inhibitory signaling [7][8][13].

Upon receptor binding, lanreotide activates pertussis toxin-sensitive inhibitory G proteins (Gi/Go), triggering multiple intracellular signaling cascades [7][8]:

• Adenylyl cyclase inhibition. Reduction of intracellular cAMP suppresses protein kinase A activity and downstream hormone exocytosis.
• Potassium channel activation. G protein beta-gamma subunits activate GIRK channels, causing membrane hyperpolarization.
• Calcium channel inhibition. Voltage-gated calcium channels (L-type and T-type) are suppressed, reducing calcium-dependent hormone secretion.
• Tyrosine phosphatase activation. SHP-1 and SHP-2 phosphatases are activated, mediating antiproliferative effects through inhibition of MAPK/ERK and PI3K/Akt pathways [8][13].

2.2 Antisecretory Effects

Through SSTR2/SSTR5 agonism on target cells, lanreotide suppresses the secretion of multiple hormones [9][12][18]:

• Growth hormone (GH): Direct inhibition of somatotroph secretion with downstream reduction of hepatic IGF-1 synthesis.
• Serotonin and other biogenic amines: Suppression from carcinoid and other neuroendocrine tumor cells.
• Glucagon, insulin, gastrin, VIP, pancreatic polypeptide, and other gut hormones.
• TSH: In rare TSH-secreting pituitary adenomas.

2.3 Antiproliferative Effects

Beyond hormonal suppression, lanreotide exerts direct and indirect antiproliferative effects on neuroendocrine tumor cells, demonstrated most convincingly in the CLARINET trial [1][8][13]:

• Direct effects: SSTR2-mediated activation of phosphotyrosine phosphatases (SHP-1, SHP-2) inhibits cell cycle progression through upregulation of p21 and p27 cyclin-dependent kinase inhibitors, and induces apoptosis via caspase activation [8][13].
• Indirect effects: Suppression of circulating growth factors (IGF-1, EGF, bFGF, VEGF), inhibition of tumor angiogenesis through reduced VEGF signaling, and immunomodulatory effects contribute to tumor growth control [8][13].

3. The Autogel Formulation

The Somatuline Autogel (Somatuline Depot in the US) represents a unique drug delivery innovation in the somatostatin analog class [5][16][18]. The formulation consists of a supersaturated aqueous solution of lanreotide acetate that spontaneously forms a semi-solid gel depot upon deep subcutaneous injection. The gel consists of self-assembling lanreotide nanotubes -- a property arising from the peptide's inherent amphiphilic character and its tendency to form ordered supramolecular structures at high concentrations.

Key characteristics of the Autogel formulation [16][18]:

• Ready-to-use prefilled syringe. No reconstitution, mixing, or preparation required, unlike octreotide LAR which requires suspension of microspheres in a diluent.
• Deep subcutaneous injection. Administered in the upper outer quadrant of the buttock, rather than intramuscularly (gluteal), reducing injection complexity.
• Self-injection capability. Patients or their partners can be trained to administer the injection at home, reducing clinic visit burden. In a prospective study, 89% of patients successfully self-injected after training [5].
• Sustained release. The gel depot provides slow, sustained lanreotide release over 28 days, with a mean terminal half-life of 23-30 days [16].
• Bioavailability. 73-85% compared to intravenous administration [16].
• Available doses. 60 mg, 90 mg, and 120 mg prefilled syringes.

This formulation stands in contrast to octreotide LAR, which uses biodegradable PLGA microspheres requiring intramuscular gluteal injection by a healthcare professional. The self-injection capability of the Autogel has been a significant practical differentiator in clinical practice [5].

4. Researched Applications

Gastroenteropancreatic Neuroendocrine Tumors (Strong Evidence -- FDA Approved)

The CLARINET trial (Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors) was the pivotal study that established lanreotide's antiproliferative indication [1]. This Phase 3, randomized, double-blind, placebo-controlled trial enrolled 204 patients with well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive, grade 1 or 2 (Ki-67 up to 10%) enteropancreatic NETs that were either metastatic or locally advanced. Patients were randomized to lanreotide 120 mg or placebo every 28 days.

At the prespecified analysis, lanreotide significantly prolonged progression-free survival compared to placebo, with a hazard ratio of 0.47 (95% CI 0.30-0.73; p=0.001). Median PFS was not reached in the lanreotide group versus 18.0 months in the placebo group. At 24 months, 65.1% of lanreotide-treated patients versus 33.0% of placebo patients had stable disease [1]. The benefit was consistent across subgroups including tumor origin (pancreatic vs midgut), hepatic tumor burden, and prior treatment status.

The CLARINET open-label extension (2016) followed 88 patients for an additional 96 weeks and confirmed the durability of the antiproliferative effect [2]. These results, combined with the earlier PROMID trial showing similar effects for octreotide [4], established somatostatin analogs as a class with antiproliferative activity in well-differentiated NETs.

The CLARINET FORTE study (2021) investigated dose intensification to 120 mg every 14 days in patients with progressive disease on standard-dose lanreotide [15]. Disease control was achieved in 61.5% of patients at 48 weeks, suggesting that dose escalation may provide a viable strategy before switching to more toxic second-line therapies such as everolimus or temozolomide.

Acromegaly (Strong Evidence -- FDA Approved)

Lanreotide Autogel is a first-line medical therapy for acromegaly, used in patients who have not achieved remission with transsphenoidal surgery or who are not surgical candidates [6][11][14]. Meta-analyses comparing lanreotide with octreotide LAR have demonstrated equivalent efficacy, with both agents normalizing IGF-1 in 50-65% and GH in 55-70% of patients [11].

In a prospective study of treatment-naive acromegaly patients, lanreotide Autogel 120 mg as primary therapy normalized IGF-1 levels in 49% of patients and achieved tumor volume reduction of more than 20% in 63% at 48 weeks [6]. Dose titration is guided by GH and IGF-1 levels, typically assessed every 3 months, with doses ranging from 60 to 120 mg every 28 days [14][18].

For patients inadequately controlled on first-generation somatostatin analogs including lanreotide, the PAOLA trial demonstrated that switching to pasireotide LAR achieved biochemical control in 15.4% versus 0% continuing on octreotide or lanreotide [20].

Carcinoid Syndrome (Strong Evidence -- FDA Approved in EU)

The ELECT trial (2014) established lanreotide as an effective treatment for carcinoid syndrome in patients previously controlled on octreotide LAR [3]. This Phase 3 study randomized 115 patients to lanreotide 120 mg or placebo every 28 days for 16 weeks. Lanreotide significantly reduced the percentage of days requiring rescue subcutaneous octreotide compared to placebo (33.7% vs 48.5%; p=0.02), confirming efficacy for symptomatic control of flushing and diarrhea [3].

5. Clinical Evidence Summary

6. Comparison with Octreotide

The clinical selection between lanreotide Autogel and octreotide LAR is often driven by practical considerations rather than efficacy differences, as both agents demonstrate comparable hormonal suppression and antiproliferative activity [9][11]:

Efficacy. Meta-analyses and indirect comparisons consistently show no significant differences in GH/IGF-1 normalization rates in acromegaly or PFS in NETs between lanreotide and octreotide [11]. The CLARINET trial (lanreotide, HR 0.47) and PROMID trial (octreotide, HR 0.34) demonstrated antiproliferative effects of comparable magnitude, though direct comparison is confounded by differing patient populations (CLARINET included pancreatic and nonfunctioning tumors; PROMID focused on midgut tumors only) [1][4].

Formulation advantages of lanreotide Autogel:

• Ready-to-use prefilled syringe (no reconstitution)
• Deep subcutaneous injection (vs intramuscular for octreotide LAR)
• Self-injection or partner injection capability
• No cold-chain interruption concerns during microsphere preparation

Formulation advantages of octreotide LAR:

• Longer clinical experience and familiarity
• Availability of oral octreotide (Mycapssa) for long-term maintenance in acromegaly
• Established role in acute management (subcutaneous/IV octreotide for acute symptoms)

Switching between agents. Patients may be switched from octreotide LAR to lanreotide Autogel (or vice versa) for tolerability, convenience, or insurance reasons. No washout period is required, and the new agent can be initiated 4 weeks after the last injection of the previous agent [11][18].

7. Dosing in Research

Acromegaly. Initiate at 90 mg deep SC every 28 days. After 3 months, titrate based on GH and IGF-1: increase to 120 mg if GH is greater than 2.5 mcg/L or IGF-1 remains elevated; decrease to 60 mg if normalized. Target is GH at or below 1.0 mcg/L and age-/sex-normalized IGF-1 [14][18].

GEP-NETs (CLARINET protocol). Lanreotide 120 mg deep SC every 28 days. Continue until disease progression or unacceptable toxicity [1][18].

Carcinoid syndrome. Lanreotide 120 mg deep SC every 28 days. Subcutaneous octreotide may be used as rescue for breakthrough symptoms [3][18].

Dose-intensified protocol (CLARINET FORTE). Lanreotide 120 mg deep SC every 14 days in patients with progressive disease on standard dosing [15].

8. Safety and Side Effects

The safety profile of lanreotide is well characterized through extensive clinical trial data and postmarketing experience and is comparable to octreotide [1][6][18].

Gastrointestinal effects. The most common adverse events include diarrhea (26-37%), abdominal pain (14-19%), nausea (11-14%), flatulence (7%), and constipation (5-8%). These effects typically diminish in frequency and severity with continued treatment and are related to suppression of pancreatic exocrine function and altered gut motility [18].

Cholelithiasis. Gallbladder sludge and gallstones develop in approximately 20-30% of patients on long-term lanreotide therapy, comparable to octreotide rates. The mechanism involves suppression of cholecystokinin-mediated gallbladder contraction and altered bile composition. Most gallstone events are asymptomatic; 5-7% of patients require cholecystectomy. Periodic gallbladder ultrasonography is recommended [18].

Injection site reactions. Pain, induration, or nodule formation at the deep subcutaneous injection site occurs in 6-9% of patients. Injection site reactions are generally mild and do not typically require treatment discontinuation [18].

Hyperglycemia and hypoglycemia. Glucose dysregulation occurs in approximately 5-14% of patients. Lanreotide suppresses both insulin and glucagon secretion, with variable net glycemic effects. Pre-existing diabetes may worsen. Hyperglycemia rates are substantially lower than with pasireotide (5-14% vs up to 70%) [18][20].

Bradycardia. Sinus bradycardia (heart rate below 60 bpm) has been reported in 3-8% of patients. QT prolongation and conduction abnormalities are uncommon but have been reported [18].

Hypothyroidism. TSH suppression leading to subclinical or overt hypothyroidism occurs in approximately 7% of patients. Periodic thyroid function monitoring is advised [18].

9. Regulatory Status

United States (FDA). Somatuline Depot (lanreotide) injection was approved in August 2007 for acromegaly and expanded in December 2014 to include unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs. Marketed by Ipsen Biopharmaceuticals [18].

European Union (EMA). Somatuline Autogel is approved across EU member states for acromegaly, GEP-NETs, carcinoid syndrome, and thyrotropinomas.

Manufacturer. Ipsen (originator; headquartered in Paris, France).

10. Pharmacokinetics

Autogel Depot Formulation

The pharmacokinetic profile of lanreotide is dominated by the unique Autogel formulation, which governs absorption, distribution, and effective elimination [16][18].

Absorption. Following deep subcutaneous injection of the Autogel formulation in the upper outer quadrant of the buttock, lanreotide is released slowly from the semi-solid gel depot formed by self-assembling peptide nanotubes. A small initial burst release occurs within the first 24 hours, followed by sustained release over the 28-day dosing interval. Peak serum concentrations (Cmax) are reached between day 1 and day 7 post-injection depending on the dose. For the 120 mg dose, Cmax is approximately 5.7-7.7 ng/mL with a mean trough concentration (Cmin) of approximately 1.8-2.4 ng/mL at day 28 [16][18]. Absolute bioavailability is 73-85% compared to intravenous administration, varying slightly with injection technique and body composition [16].

Distribution. Plasma protein binding of lanreotide is moderate (approximately 78-85%), primarily to lipoproteins and to a lesser degree albumin. The apparent volume of distribution at steady state is approximately 16-20 L following IV administration, indicating moderate tissue distribution. Lanreotide distributes to target tissues expressing SSTR2/SSTR5 including the pituitary, pancreas, gastrointestinal tract, and neuroendocrine tumor tissue [18].

Metabolism and elimination. Lanreotide is metabolized primarily through proteolytic degradation to smaller peptide fragments and amino acids. No active metabolites have been identified. The terminal elimination half-life following Autogel injection is 23-30 days, driven entirely by the slow release from the depot (flip-flop kinetics). In contrast, the true systemic half-life after intravenous administration is only approximately 2 hours, confirming that the prolonged apparent half-life is a formulation-driven absorption rate phenomenon [16][18]. Lanreotide is excreted primarily through the biliary route, with renal elimination accounting for less than 5% of total clearance. No dose adjustment is required for mild-to-moderate renal or hepatic impairment; data are limited for severe impairment [18].

Steady-state considerations. Due to the long effective half-life, steady-state serum concentrations are achieved after approximately 4-5 injections (4-5 months of dosing). Clinical biochemical assessments (GH, IGF-1 for acromegaly; chromogranin A for NETs) should therefore be performed no earlier than 3 months after treatment initiation to allow for steady-state attainment [14][18].

Pharmacokinetic variability. Interpatient variability in lanreotide pharmacokinetics is moderate (CV approximately 30-40%), influenced by injection technique (depth of subcutaneous placement), body mass index, and local tissue perfusion. Proper deep subcutaneous injection is critical for consistent drug release; superficial injection may result in erratic absorption and reduced efficacy [16][18].

Comparison with Octreotide LAR Pharmacokinetics

| Parameter | Lanreotide Autogel (120 mg) | Octreotide LAR (30 mg) | |---|---|---| | Formulation | Supersaturated aqueous gel | PLGA microspheres | | Route | Deep subcutaneous | Intramuscular (gluteal) | | Cmax timing | Day 1-7 | Day 14-28 (delayed release) | | Effective half-life | 23-30 days | 28-35 days | | Bioavailability | 73-85% | 60-65% | | Steady-state time | 4-5 injections | 3-4 injections | | Self-injection | Yes | No (requires HCP) | | Reconstitution | None (prefilled) | Required (microsphere suspension) |

11. Dose-Response Relationships

Growth Hormone / IGF-1 Dose-Response in Acromegaly

Lanreotide demonstrates a clear dose-dependent suppression of GH and IGF-1 in acromegaly, with the dose range of 60-120 mg every 28 days spanning the clinically relevant portion of the dose-response curve [6][14][18].

Dose titration data (Chanson et al. 2008). In a prospective 48-week titration study, progressive dose escalation from 60 mg to 90 mg to 120 mg every 28 days produced stepwise improvements in biochemical control [14]:

| Dose | IGF-1 Normalization Rate | Mean GH Suppression | |---|---|---| | 60 mg q28d | 28-35% | GH reduction of approximately 45-55% | | 90 mg q28d | 40-50% | GH reduction of approximately 55-65% | | 120 mg q28d | 49-65% | GH reduction of approximately 65-75% |

The dose-response relationship approaches a plateau at 120 mg, with diminishing incremental benefit above this dose for the standard q28d interval. This pharmacological ceiling reflects near-maximal SSTR2 occupancy at trough concentrations achieved with 120 mg [14][18].

Dose Intensification for NETs (CLARINET FORTE)

For patients with progressive GEP-NETs on standard-dose lanreotide (120 mg q28d), increasing injection frequency to every 14 days effectively doubles the average steady-state drug exposure. In the CLARINET FORTE study, this dose-intensified regimen achieved a disease control rate of 61.5% at 48 weeks in patients who had progressed on the standard regimen, supporting the concept that higher sustained drug levels can overcome partial resistance in tumors with moderate SSTR2 expression [15].

Carcinoid Symptom Dose-Response

In carcinoid syndrome, the 120 mg q28d dose is used uniformly (without titration) because symptom control correlates with sustained suppression of serotonin and other vasoactive peptides, which requires continuous SSTR2 engagement. The ELECT trial confirmed that 120 mg q28d provides clinically meaningful symptom control, with rescue octreotide use reduced from 48.5% to 33.7% of days [3].

12. Comparative Effectiveness

Lanreotide vs. Octreotide LAR

These two first-generation somatostatin analogs are the primary comparators in clinical practice across all approved indications [9][11].

Acromegaly. Multiple meta-analyses and head-to-head indirect comparisons show no clinically meaningful difference in biochemical control rates. A comprehensive 2013 meta-analysis of all available RCT data found GH normalization rates of 55-70% and IGF-1 normalization rates of 50-65% for both agents, with overlapping confidence intervals and no statistically significant between-agent differences [11]. The Colao 2019 clinical practice update confirmed that the choice between lanreotide and octreotide in acromegaly should be guided by practical considerations (self-injection capability, patient preference, insurance coverage) rather than anticipated efficacy differences [11].

GEP-NETs (antiproliferative). The CLARINET trial (lanreotide, HR 0.47 for PFS vs placebo) and PROMID trial (octreotide, HR 0.34 for time to tumor progression vs placebo) both demonstrated significant antiproliferative effects. While the hazard ratios numerically favor octreotide, direct comparison is confounded by substantial differences in patient populations: PROMID enrolled exclusively midgut NET patients, while CLARINET included both pancreatic and midgut NETs with higher Ki-67 thresholds (up to 10% vs up to 2%) [1][4]. Current NCCN and ENETS guidelines recommend either agent interchangeably as first-line antiproliferative therapy for well-differentiated GEP-NETs [9][17].

Carcinoid syndrome. The ELECT trial demonstrated that lanreotide 120 mg is noninferior to octreotide LAR for symptom control in patients previously controlled on octreotide, enabling cross-switching between agents for convenience or tolerability reasons [3].

Lanreotide vs. Pasireotide

Pasireotide (SOM230) is a second-generation pan-somatostatin receptor analog with broader SSTR binding [19][20].

Acromegaly (second-line setting). The PAOLA trial demonstrated that pasireotide LAR achieved biochemical control in 15.4% of patients refractory to octreotide or lanreotide vs 0% continuing on first-generation SSAs. However, hyperglycemia occurred in 57.3% of pasireotide patients vs 21.7% of first-generation SSA patients. This establishes pasireotide as a rescue option for lanreotide/octreotide failures, but the hyperglycemia burden limits its positioning [20].

NETs. Pasireotide LAR 60 mg failed to demonstrate superiority over high-dose octreotide LAR 40 mg for refractory carcinoid symptoms (p=0.28), and its hyperglycemia profile makes it a less favorable option than dose-intensified lanreotide (CLARINET FORTE approach) in patients progressing on standard somatostatin analog therapy [10].

Lanreotide vs. Everolimus/Temozolomide (NET Second-Line)

In progressive GEP-NETs, the key clinical decision is whether to dose-intensify lanreotide (q14d per CLARINET FORTE) or switch to second-line agents such as everolimus (RADIANT-3/4 trials) or temozolomide-based chemotherapy. The CLARINET FORTE disease control rate of 61.5% compares favorably to everolimus PFS data, while maintaining the favorable toxicity profile of somatostatin analogs. Dose-intensified lanreotide is increasingly used as a bridge strategy to delay the initiation of more toxic second-line therapies [15].

13. Enhanced Safety Profile

Comprehensive Adverse Event Analysis

The safety profile of lanreotide Autogel has been thoroughly characterized across more than 3,500 patient-years of exposure in clinical trials and postmarketing surveillance [1][18].

Gastrointestinal tolerability. GI adverse events are the most common class effects, occurring in 40-55% of patients overall but leading to treatment discontinuation in only 2-3%. The pattern follows a consistent temporal trajectory: GI symptoms (diarrhea, abdominal pain, nausea, flatulence) peak during the first 3-6 months of treatment and progressively diminish thereafter, likely reflecting adaptation of the gastrointestinal tract to reduced pancreatic exocrine function and altered gut motility [18].

| GI Adverse Event | Incidence (All Grades) | Severe (Grade 3+) | Leading to Discontinuation | |---|---|---|---| | Diarrhea | 26-37% | 3-5% | 1-2% | | Abdominal pain | 14-19% | 1-2% | 0.5-1% | | Nausea | 11-14% | 0.5-1% | 0.3-0.5% | | Flatulence | 7-10% | rare | rare | | Constipation | 5-8% | rare | rare |

Cholelithiasis surveillance. Gallstone-related events are a class effect of all somatostatin analogs, driven by CCK suppression with reduced gallbladder contractility and bile stasis. In pooled lanreotide safety analyses, the incidence of gallstones or biliary sludge is approximately 20-30% with long-term use. However, the majority (75-80%) of detected gallstones are asymptomatic and identified on routine ultrasonographic surveillance. Symptomatic cholelithiasis requiring cholecystectomy occurs in approximately 5-7% of patients. Current guidelines recommend baseline gallbladder ultrasound and periodic surveillance (every 6-12 months) during treatment [18].

Glucose metabolism. Lanreotide's effect on glucose metabolism is substantially more favorable than pasireotide. By suppressing both insulin and glucagon secretion (primarily via SSTR2), the net glycemic effect is relatively balanced, with clinically significant hyperglycemia occurring in only 5-14% of patients. This contrasts markedly with pasireotide, where SSTR5-mediated preferential insulin suppression produces hyperglycemia in 57-73% of patients. In patients with pre-existing diabetes, HbA1c typically increases by 0.2-0.5% during lanreotide therapy, manageable with standard glucose-lowering agents [18][20].

Cardiac monitoring. Sinus bradycardia (HR below 60 bpm) occurs in 3-8% of patients and is generally asymptomatic. Clinically significant QT prolongation is rare (under 1%). ECG monitoring is recommended at baseline and considered periodically in patients with pre-existing cardiac conduction abnormalities or those receiving concomitant QT-prolonging medications [18].

Injection site management. Deep subcutaneous injection site reactions (pain, induration, nodule) occur in 6-9% of patients. These are predominantly mild (grade 1-2) and rarely require treatment modification. Proper injection technique -- deep subcutaneous placement in the upper outer quadrant of the buttock with slow injection -- minimizes injection site complications. The self-injection training program has been shown to maintain low injection site reaction rates comparable to healthcare professional administration [5][18].

Long-term safety. Data from the CLARINET open-label extension and long-term acromegaly registries confirm no cumulative toxicity signals with treatment durations exceeding 5-10 years. No increased risk of malignancy, cardiovascular events, or organ toxicity has been identified with chronic lanreotide use [2][18].

14. Related Peptides

See also: Octreotide (Sandostatin), Pasireotide (Signifor), Somatostatin (SRIF-14)

15. References

1. [1] Caplin ME, Pavel M, Cwikla JB, et al. (2014). Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET). N Engl J Med. DOI PubMed
2. [2] Caplin ME, Pavel M, Cwikla JB, et al. (2016). Anti-tumour Effects of Lanreotide for Pancreatic and Intestinal Neuroendocrine Tumours -- The CLARINET Open-Label Extension Study. Endocr Relat Cancer. DOI PubMed
3. [3] Vinik AI, Wolin EM, Liyanage N, et al. (2014). Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT). Endocr Pract. DOI PubMed
4. [4] Rinke A, Mueller HH, Schade-Brittinger C, et al. (2009). Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID). J Clin Oncol. DOI PubMed
5. [5] Caron P, Beckers A, Cullen DR, et al. (2002). Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly. J Clin Endocrinol Metab. DOI PubMed
6. [6] Melmed S, Cook D, Schopohl J, et al. (2010). Rapid and Sustained Reduction of Serum Growth Hormone and Insulin-like Growth Factor-1 in Patients with Acromegaly Receiving Lanreotide Autogel Therapy. Pituitary. DOI PubMed
7. [7] Patel YC. (1999). Somatostatin and Its Receptor Family. Front Neuroendocrinol. DOI PubMed
8. [8] Cakir M, Dworakowska D, Grossman AB. (2010). Somatostatin Receptor Biology in Neuroendocrine and Pituitary Tumours: Part 1 -- Molecular Pathways. J Cell Mol Med. DOI PubMed
9. [9] Modlin IM, Pavel M, Kidd M, Gustafsson BI. (2010). Review Article -- Somatostatin Analogues in the Treatment of Gastroenteropancreatic Neuroendocrine (Carcinoid) Tumours. Aliment Pharmacol Ther. DOI PubMed
10. [10] Wolin EM, Jarzab B, Eriksson B, et al. (2015). Phase III Study of Pasireotide Long-Acting Release in Patients with Metastatic Neuroendocrine Tumors and Carcinoid Symptoms Refractory to Available Somatostatin Analogues. Drug Des Devel Ther. DOI PubMed
11. [11] Colao A, Auriemma RS, Pivonello R, et al. (2019). Optimising the Management of Patients with Acromegaly -- An Update. Endocr Rev. DOI PubMed
12. [12] Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. (1996). Octreotide. N Engl J Med. DOI PubMed
13. [13] Barbieri F, Bajetto A, Pattarozzi A, et al. (2013). Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm. Int J Pept. DOI PubMed
14. [14] Chanson P, Borson-Chazot F, Kuhn JM, et al. (2008). Control of IGF-I Levels with Titrated Dosing of Lanreotide Autogel Over 48 Weeks in Patients with Acromegaly. Clin Endocrinol (Oxf). DOI PubMed
15. [15] Caplin ME, Mielke S, Burch PA, et al. (2021). CLARINET FORTE -- Lanreotide Autogel 120 mg Every 14 Days for Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours. Oncologist. DOI PubMed
16. [16] Bronstein M, Musolino N, Jallad R, et al. (2005). Pharmacokinetic Profile of Lanreotide Autogel in Patients with Acromegaly After Four Deep Subcutaneous Injections of 60, 90, or 120 mg Every 28 Days. Clin Endocrinol (Oxf). DOI PubMed
17. [17] Oberg K, Kvols L, Caplin M, et al. (2004). Consensus Report on the Use of Somatostatin Analogs for the Management of Neuroendocrine Tumors of the Gastroenteropancreatic System. Ann Oncol. DOI PubMed
18. [18] Somatuline Depot Prescribing Information (2024). Somatuline Depot (Lanreotide) Injection: Full Prescribing Information. Ipsen Biopharmaceuticals / FDA. PubMed
19. [19] Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. (2002). SOM230: A Novel Somatostatin Peptidomimetic with Broad SRIF Receptor Binding and a Unique Antisecretory Profile. Eur J Endocrinol. DOI PubMed
20. [20] Colao A, Petersenn S, Newell-Price J, et al. (2014). Pasireotide versus Continued Treatment with Octreotide or Lanreotide in Patients with Inadequately Controlled Acromegaly (PAOLA). Lancet Diabetes Endocrinol. DOI PubMed